Search

Your search keyword '"Chougnet, Cecile N."' showing total 13 results
Start Over Author "Chougnet, Cecile N."
13 results on '"Chougnet, Cecile N."'

1. Factors associated with survival in anaplastic thyroid carcinoma: A multi-center study from the ENDOCAN-TUTHYREF network

Author

JANNIN, Arnaud, primary, Giudici, Fabiola, additional, de la Fouchardiere, Christelle, additional, Al Ghuzlan, Abir, additional, Wassermann, Johanna, additional, Chougnet, Cecile N, additional, Drui, Delphine, additional, Godbert, Yann, additional, Illouz, Frédéric, additional, Bardet, Stéphane, additional, Zanetta, Sylvie, additional, Roudaut, Nathalie, additional, Batisse-Lignier, Marie, additional, Groussin, Lionel, additional, klein, marc olivier, additional, Zerdoud, Slimane, additional, Lamartina, Livia, additional, Baudin, Eric, additional, Decaussin-Petrucci, Myriam, additional, Leteurtre, Emmanuelle, additional, Borson-Chazot, Francoise, additional, Do Cao, Christine, additional, Borget, Isabelle, additional, and Hadoux, Julien, additional

Published
2023
Full Text
View/download PDF

3. Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.

Author

Jannin, Arnaud, Giudici, Fabiola, de la Fouchardière, Christelle, Al Ghuzlan, Abir, Wassermann, Johanna, Chougnet, Cecile N., Drui, Delphine, Godbert, Yann, Ilouz, Frédéric, Bardet, Stéphane, Zanetta, Sylvie, Roudaut, Nathalie, Batisse Lignier, Marie, Groussin, Lionel, Klein, Marc, Zerdoud, Slimane, Lamartina, Livia, Baudin, Eric, Decaussin-Petrucci, Myriam, and Leteurtre, Emmanuelle

Subjects
ANAPLASTIC thyroid cancer, THYROID cancer, RADIOTHERAPY, PROPORTIONAL hazards models, NEUTROPHIL lymphocyte ratio, COMBINED modality therapy
Abstract

Background: Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the factors associated with overall survival (OS) of patients with ATC using multicenter real-world data from a national tertiary care center network in France. Methods: In this multicenter, retrospective cohort study, all patients with ATC diagnosed between 2010 and 2020 were identified from the national database of the French ENDOCAN-TUTHYREF network. Factors associated with OS were examined in multivariable analyses using Cox proportional hazards models. Results: The study included 360 patients. Of these, 220 (61%) were female and the median age was 72 years (interquartile range: 62–80). The percentages of patients with pure and mixed (synchronously-transformed) ATC (p-ATC and st-ATC) were 62.5% and 26.7%, respectively. The median OS was 6.8 months [confidence interval, CI: 5.5–8.1]: not reached for stage IVa, 11.4 months [8.2–17.8] for IVb, and 4.6 months [3.5–5.7] for IVc. Surgery, radiation therapy to the neck, chemotherapy, and best supportive care were administered to 69 (19.2%), 214 (59.4%), 254 (70.6%), and 66 (18.3%) patients, respectively. In a multivariable analysis, including stage IVb–IVc patients, significantly higher OS was observed in patients with Eastern Cooperative Oncology Group performance-status of 0–1 (hazard ratio [HR], 0.6; [CI, 0.4–0.9], p < 0.02), stage IVb [HR, 0.5; CI, 0.4–0.8, p < 0.001], and multimodal treatment (surgery and chemoradiotherapy) [HR, 0.07; CI, 0.04–0.1, p < 0.001]. Variables associated with significantly worse OS included: p-ATC (vs. st-ATC) [HR, 1.83; CI, 1.33–2.51, p = 0.001] and a neutrophil-to-lymphocyte ratio (NLR) >5.05 [HR, 2.05, CI, 1.39–3.05, p < 0.001]. Conclusions: Factors independently associated with improved OS in ATC included: European Cooperative Oncology Group performance status, disease stage, multimodality treatment, synchronously transformed ATC, and lower NLR. Long-term OS was observed in selected patients with ATC who underwent multimodal treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

4. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer

Author

Leboulleux, Sophie, primary, Bournaud, Claire, additional, Chougnet, Cecile N., additional, Zerdoud, Slimane, additional, Al Ghuzlan, Abir, additional, Catargi, Bogdan, additional, Do Cao, Christine, additional, Kelly, Antony, additional, Barge, Marie-Luce, additional, Lacroix, Ludovic, additional, Dygai, Inna, additional, Vera, Pierre, additional, Rusu, Daniela, additional, Schneegans, Olivier, additional, Benisvy, Danielle, additional, Klein, Marc, additional, Roux, Julie, additional, Eberle, Marie-Claude, additional, Bastie, Delphine, additional, Nascimento, Camila, additional, Giraudet, Anne-Laure, additional, Le Moullec, Nathalie, additional, Bardet, Stéphane, additional, Drui, Delphine, additional, Roudaut, Nathalie, additional, Godbert, Yann, additional, Morel, Olivier, additional, Drutel, Anne, additional, Lamartina, Livia, additional, Schvartz, Claire, additional, Velayoudom, Fritz-Line, additional, Schlumberger, Martin-Jean, additional, Leenhardt, Laurence, additional, and Borget, Isabelle, additional

Published
2022
Full Text
View/download PDF

5. Estimabl2: Is There a Need for Radioiodine Ablation in Low Risk Differentiated Thyroid Cancer (DTC) Patients?: Results From the French Randomized Phase III Prospective Trial on 776 Patients (NCT 01837745)

Author

Leboulleux, Sophie, primary, Bournaud, Claire, additional, Chougnet, Cecile N, additional, Zerdoud, Slimane, additional, Catargi, Bogdan Nicolescu, additional, Cao, Christine Do, additional, Kelly, Antony, additional, Barge, Marie-Luce, additional, Dygay, Inna, additional, Vera, Pierre, additional, Rusu, Daniela, additional, Schneegans, Olivier, additional, Benisvy, Danielle, additional, Klein, Marc, additional, Roux, Julie, additional, Eberle, Marie-Claude, additional, Bastie, Delphine, additional, Nascimento, Camila, additional, Giraudet, Anne-Laure, additional, Moullec, Nathalie Le, additional, Bardet, Stephane, additional, Drui, Delphine, additional, Roudaut, Nathalie, additional, Godbert, Yann, additional, Morel, Olivier, additional, Anne, Drutel, additional, Schwartz, Claire, additional, Velayoudoum, Fritzline, additional, Schlumberger, Martin Jean, additional, Leenhardt, Laurence, additional, and Borget, Isabelle, additional

Published
2021
Full Text
View/download PDF

7. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach

Author

Rozenblum, Laura, primary, Mokrane, Fatima-Zohra, additional, Yeh, Randy, additional, Sinigaglia, Mathieu, additional, Besson, Florent L., additional, Seban, Romain-David, additional, Zadro, Charline, additional, Dierickx, Lawrence, additional, Chougnet, Cecile N, additional, Partouche, Ephraim, additional, Revel-Mouroz, Paul, additional, Zhao, Binsheng, additional, Otal, Philippe, additional, Schwartz, Lawrence H., additional, and Dercle, Laurent, additional

Published
2020
Full Text
View/download PDF

8. Vandetanib for the Treatment of Advanced Medullary Thyroid Cancer Outside a Clinical Trial: Results from a French Cohort

Author

Chougnet, Cecile N., primary, Borget, Isabelle, additional, Leboulleux, Sophie, additional, de la Fouchardiere, Christelle, additional, Bonichon, Françoise, additional, Criniere, Lise, additional, Niccoli, Patricia, additional, Bardet, Stéphane, additional, Schneegans, Olivier, additional, Zanetta, Sylvie, additional, Schvartz, Claire, additional, Drui, Delphine, additional, Chauffert, Bruno, additional, Rohmer, Vincent, additional, and Schlumberger, Martin, additional

Published
2015
Full Text
View/download PDF

10. Are G3 ENETS neuroendocrine neoplasms heterogeneous?

Author

Vélayoudom-Céphise, Fritz-Line, primary, Duvillard, Pierre, additional, Foucan, Lydia, additional, Hadoux, Julien, additional, Chougnet, Cecile N, additional, Leboulleux, Sophie, additional, Malka, David, additional, Guigay, Joël, additional, Goere, Diane, additional, Debaere, Thierry, additional, Caramella, Caroline, additional, Schlumberger, Martin, additional, Planchard, David, additional, Elias, Dominique, additional, Ducreux, Michel, additional, Scoazec, Jean-Yves, additional, and Baudin, Eric, additional

Published
2013
Full Text
View/download PDF

11. Frequency and characterization of gastro–entero–pancreatic neuroendocrine tumor patients with high-grade of uptake at somatostatin receptor scintigraphy

Author

Chougnet, Cecile N, primary, Leboulleux, Sophie, additional, Caramella, Caroline, additional, Lumbroso, Jean, additional, Borget, Isabelle, additional, Déandreis, Désirée, additional, Duvillard, Pierre, additional, Elias, Dominique, additional, de Baere, Thierry, additional, Vélayoudom-Céphise, Fritz-Line, additional, Guigay, Joël, additional, Ducreux, Michel, additional, Schlumberger, Martin, additional, and Baudin, Eric, additional

Published
2013
Full Text
View/download PDF

12. Post-Radioiodine Treatment Whole Body Scan in the Era of Fluorodesoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with elevated serum thyroglobulin levels

Author

Leboulleux, Sophie, primary, El Bez, Intidhar, additional, BORGET, Isabelle, additional, Elleuch, Manel, additional, Deandreis, Desiree, additional, Al Ghuzlan, Abir, additional, Chougnet, Cecile N, additional, Bidault, François, additional, Mirghani, Haitham, additional, Lumbroso, Jean, additional, Hartl, Dana M, additional, BAUDIN, Eric, additional, and Schlumberger, Martin, additional

Published
2012
Full Text
View/download PDF

13. [Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].

Author

Chougnet CN, Schlumberger M, Leboulleux S, and Baudin E

Subjects
Antineoplastic Agents adverse effects, Carcinoma, Medullary genetics, Carcinoma, Medullary pathology, Carcinoma, Medullary secondary, Carcinoma, Neuroendocrine, Humans, Piperidines adverse effects, Proto-Oncogene Proteins c-ret antagonists & inhibitors, Proto-Oncogene Proteins c-ret genetics, Quinazolines adverse effects, Rare Diseases pathology, Thyroid Neoplasms genetics, Thyroid Neoplasms pathology, Antineoplastic Agents therapeutic use, Carcinoma, Medullary drug therapy, Piperidines therapeutic use, Quinazolines therapeutic use, Rare Diseases drug therapy, Thyroid Neoplasms drug therapy
Abstract

Medullary thyroid cancer (MTC) is a rare cancer. Vandetanib, a RET tyrosine-kinase inhibitor, significantly increased progression free survival and is the first treatment approved in France for unresectable, locally advanced or metastatic MTC that is symptomatic or progressive. Most frequents adverse events are diarrhea, folliculitis and asthenia. The prolongation of the QT interval on electrocardiogram is frequent but in the most of cases not clinically relevant. A good selection of the patients who could benefit from this treatment and management of side effect are important for the risk-benefit assessment.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results